Expression and determination of biomarkers in diabetic retinopathy
10.3760/cma.j.cn115989-20200417-00269
- VernacularTitle:糖尿病视网膜病变生物标志物的表达与测定
- Author:
Yilin JIANG
1
;
Xiaomin ZHANG
;
Xiaorong LI
Author Information
1. 天津医科大学眼科医院 天津医科大学眼视光学院 天津医科大学眼科研究所 天津市视网膜功能与疾病重点实验室 天津市眼科学与视觉科学国际联合研究中心，天津 300384
- Keywords:
Diabetic retinopathy;
Biomarker;
Diagnosis;
Therapy
- From:
Chinese Journal of Experimental Ophthalmology
2022;40(9):859-863
- CountryChina
- Language:Chinese
-
Abstract:
Diabetic retinopathy (DR) is a kind of common vascular complications in diabetes and one of the leading causes of irreversible blindness.It is characterized by leaky retinal vasculature, neovascularization and fiber membrane proliferation.Although there are various DR treatments, most of them aim at middle and late stage of the disease and have limited efficacy.Therefore, early diagnosis and precise treatment of DR are important.In recent years, the research of biomarkers related to DR has developed rapidly, which plays an important role in the risk assessment and early intervention of the disease.Nowadays, classic biomarkers such as HbA1c have been widely used in clinical practice.With the further study on DR, inflammatory biomarkers and angiogenesis-related biomarkers have been found to be closely related to the occurrence and development of the disease.At the same time, with the progress of modern technology, advanced equipment have built a broad platform for the exploration of DR biomarkers.Omics biomarkers, imaging biomarkers and artificial intelligence have become the focus of research and made important contributions to the early treatment of DR.This article summarized the key progress related to the DR biomarkers research to provide new clinical strategies in the efficient prevention, control and treatment of DR.
